PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32475915-0	2020	Ziyuglycoside II Inhibits Rotavirus Induced Diarrhea Possibly via TLR4/NF-kappaB Pathways.	ziyuglycoside II	0-16	toll like receptor 4	Homo sapiens	66-70
33071789-6	2020	Mechanism indicated that Ziyu II-induced autophagy by inhibiting Akt/mTOR pathway.	ziyuglycoside II	25-32	AKT serine/threonine kinase 1	Homo sapiens	65-68
33071789-6	2020	Mechanism indicated that Ziyu II-induced autophagy by inhibiting Akt/mTOR pathway.	ziyuglycoside II	25-32	mechanistic target of rapamycin kinase	Homo sapiens	69-73
33071789-7	2020	Akt reactivation partially reduced Ziyu II-induced LC3-II turnover and LC3 puncta accumulation.	ziyuglycoside II	35-42	AKT serine/threonine kinase 1	Homo sapiens	0-3
32475915-7	2020	Moreover, Ziyuglycoside II reversed RV-induced downregulation of anti-inflammatory cytokine interleukin (IL)-10 and upregulation of pro-inflammatory factors, such as interferon-gamma (IFN-gamma), IL-1beta, IL-6, and tumor necrosis factor (TNF-alpha).	ziyuglycoside II	10-26	interleukin 6	Homo sapiens	206-210
32475915-7	2020	Moreover, Ziyuglycoside II reversed RV-induced downregulation of anti-inflammatory cytokine interleukin (IL)-10 and upregulation of pro-inflammatory factors, such as interferon-gamma (IFN-gamma), IL-1beta, IL-6, and tumor necrosis factor (TNF-alpha).	ziyuglycoside II	10-26	tumor necrosis factor	Homo sapiens	216-237
32475915-7	2020	Moreover, Ziyuglycoside II reversed RV-induced downregulation of anti-inflammatory cytokine interleukin (IL)-10 and upregulation of pro-inflammatory factors, such as interferon-gamma (IFN-gamma), IL-1beta, IL-6, and tumor necrosis factor (TNF-alpha).	ziyuglycoside II	10-26	tumor necrosis factor	Homo sapiens	239-248
33069969-6	2020	Moreover, ZGS II treatment altered the differentially expressed genes (DEGs) with known functions in HSPC differentiation and mobilization (Cxcl12, Col1a2, and Sparc) and the surface markers of neutrophilic precursors or neutrophils (Ngp and CD177).	ziyuglycoside II	10-16	chemokine (C-X-C motif) ligand 12	Mus musculus	140-146
33069969-6	2020	Moreover, ZGS II treatment altered the differentially expressed genes (DEGs) with known functions in HSPC differentiation and mobilization (Cxcl12, Col1a2, and Sparc) and the surface markers of neutrophilic precursors or neutrophils (Ngp and CD177).	ziyuglycoside II	10-16	collagen, type I, alpha 2	Mus musculus	148-154
33069969-6	2020	Moreover, ZGS II treatment altered the differentially expressed genes (DEGs) with known functions in HSPC differentiation and mobilization (Cxcl12, Col1a2, and Sparc) and the surface markers of neutrophilic precursors or neutrophils (Ngp and CD177).	ziyuglycoside II	10-16	secreted acidic cysteine rich glycoprotein	Mus musculus	160-165
33069969-6	2020	Moreover, ZGS II treatment altered the differentially expressed genes (DEGs) with known functions in HSPC differentiation and mobilization (Cxcl12, Col1a2, and Sparc) and the surface markers of neutrophilic precursors or neutrophils (Ngp and CD177).	ziyuglycoside II	10-16	neutrophilic granule protein	Mus musculus	234-237
33069969-6	2020	Moreover, ZGS II treatment altered the differentially expressed genes (DEGs) with known functions in HSPC differentiation and mobilization (Cxcl12, Col1a2, and Sparc) and the surface markers of neutrophilic precursors or neutrophils (Ngp and CD177).	ziyuglycoside II	10-16	CD177 antigen	Mus musculus	242-247
32475915-8	2020	Moreover, Ziyuglycoside II administration and ribavirin blocked toll-like receptor 4 (TLR4)/nuclear factor kappa-B (NF-kappaB) signaling pathway both in mRNA and protein level, which was paralleled with immunohistochemical assay.	ziyuglycoside II	10-26	toll like receptor 4	Homo sapiens	64-84
32475915-0	2020	Ziyuglycoside II Inhibits Rotavirus Induced Diarrhea Possibly via TLR4/NF-kappaB Pathways.	ziyuglycoside II	0-16	nuclear factor kappa B subunit 1	Homo sapiens	71-80
32475915-8	2020	Moreover, Ziyuglycoside II administration and ribavirin blocked toll-like receptor 4 (TLR4)/nuclear factor kappa-B (NF-kappaB) signaling pathway both in mRNA and protein level, which was paralleled with immunohistochemical assay.	ziyuglycoside II	10-26	toll like receptor 4	Homo sapiens	86-90
32475915-8	2020	Moreover, Ziyuglycoside II administration and ribavirin blocked toll-like receptor 4 (TLR4)/nuclear factor kappa-B (NF-kappaB) signaling pathway both in mRNA and protein level, which was paralleled with immunohistochemical assay.	ziyuglycoside II	10-26	nuclear factor kappa B subunit 1	Homo sapiens	116-125
32475915-7	2020	Moreover, Ziyuglycoside II reversed RV-induced downregulation of anti-inflammatory cytokine interleukin (IL)-10 and upregulation of pro-inflammatory factors, such as interferon-gamma (IFN-gamma), IL-1beta, IL-6, and tumor necrosis factor (TNF-alpha).	ziyuglycoside II	10-26	interleukin 10	Homo sapiens	92-111
32475915-12	2020	Ziyuglycoside II administration inhibited TLR4/NF-kappaB pathway and inflammatory response and improved RV-induced diarrhea.	ziyuglycoside II	0-16	toll like receptor 4	Homo sapiens	42-46
32475915-12	2020	Ziyuglycoside II administration inhibited TLR4/NF-kappaB pathway and inflammatory response and improved RV-induced diarrhea.	ziyuglycoside II	0-16	nuclear factor kappa B subunit 1	Homo sapiens	47-56
32475915-7	2020	Moreover, Ziyuglycoside II reversed RV-induced downregulation of anti-inflammatory cytokine interleukin (IL)-10 and upregulation of pro-inflammatory factors, such as interferon-gamma (IFN-gamma), IL-1beta, IL-6, and tumor necrosis factor (TNF-alpha).	ziyuglycoside II	10-26	interferon gamma	Homo sapiens	166-182
32475915-7	2020	Moreover, Ziyuglycoside II reversed RV-induced downregulation of anti-inflammatory cytokine interleukin (IL)-10 and upregulation of pro-inflammatory factors, such as interferon-gamma (IFN-gamma), IL-1beta, IL-6, and tumor necrosis factor (TNF-alpha).	ziyuglycoside II	10-26	interferon gamma	Homo sapiens	184-193
32475915-7	2020	Moreover, Ziyuglycoside II reversed RV-induced downregulation of anti-inflammatory cytokine interleukin (IL)-10 and upregulation of pro-inflammatory factors, such as interferon-gamma (IFN-gamma), IL-1beta, IL-6, and tumor necrosis factor (TNF-alpha).	ziyuglycoside II	10-26	interleukin 1 alpha	Homo sapiens	196-204
31525383-5	2019	The results showed that the treatment of Ziyu II could inhibit EMT, reverse anoikis resistance and subsequently suppress cell migration and invasion in MDA-MB-231 cells, which was associated with the inactivation of Src/EGFR-dependent ITGB4/FAK signaling and subsequent Akt and p38MAPK signaling pathways.	ziyuglycoside II	41-48	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	216-219
31525383-5	2019	The results showed that the treatment of Ziyu II could inhibit EMT, reverse anoikis resistance and subsequently suppress cell migration and invasion in MDA-MB-231 cells, which was associated with the inactivation of Src/EGFR-dependent ITGB4/FAK signaling and subsequent Akt and p38MAPK signaling pathways.	ziyuglycoside II	41-48	epidermal growth factor receptor	Homo sapiens	220-224
31525383-5	2019	The results showed that the treatment of Ziyu II could inhibit EMT, reverse anoikis resistance and subsequently suppress cell migration and invasion in MDA-MB-231 cells, which was associated with the inactivation of Src/EGFR-dependent ITGB4/FAK signaling and subsequent Akt and p38MAPK signaling pathways.	ziyuglycoside II	41-48	integrin subunit beta 4	Homo sapiens	235-240
31525383-5	2019	The results showed that the treatment of Ziyu II could inhibit EMT, reverse anoikis resistance and subsequently suppress cell migration and invasion in MDA-MB-231 cells, which was associated with the inactivation of Src/EGFR-dependent ITGB4/FAK signaling and subsequent Akt and p38MAPK signaling pathways.	ziyuglycoside II	41-48	protein tyrosine kinase 2	Homo sapiens	241-244
31525383-5	2019	The results showed that the treatment of Ziyu II could inhibit EMT, reverse anoikis resistance and subsequently suppress cell migration and invasion in MDA-MB-231 cells, which was associated with the inactivation of Src/EGFR-dependent ITGB4/FAK signaling and subsequent Akt and p38MAPK signaling pathways.	ziyuglycoside II	41-48	AKT serine/threonine kinase 1	Homo sapiens	270-273
28718964-4	2017	The underlying antiangiogenic mechanism of ziyuglycoside II correlated with blocking vascular endothelial growth factor receptor-2 and the fibroblast growth factor receptor-1 mediated signaling pathway.	ziyuglycoside II	43-59	kinase insert domain protein receptor	Mus musculus	85-130
31029785-3	2019	The anticancer effect of ziyuglycoside II was examined in HCT116 (as p53 normal cells) and SW480 (as p53 mutant cells) colon cancer cells.	ziyuglycoside II	25-41	tumor protein p53	Homo sapiens	69-72
31029785-6	2019	Apoptosis caused by p53 phosphorylation following ziyuglycoside II treatment in HCT116 cells involved activation of caspases, increased expression of BAX, mitochondrial cytochrome c and apoptosis inducing factor (AIF) release, while BCL-2 became down-regulated.	ziyuglycoside II	50-66	tumor protein p53	Homo sapiens	20-23
31029785-6	2019	Apoptosis caused by p53 phosphorylation following ziyuglycoside II treatment in HCT116 cells involved activation of caspases, increased expression of BAX, mitochondrial cytochrome c and apoptosis inducing factor (AIF) release, while BCL-2 became down-regulated.	ziyuglycoside II	50-66	BCL2 associated X, apoptosis regulator	Homo sapiens	150-153
31029785-6	2019	Apoptosis caused by p53 phosphorylation following ziyuglycoside II treatment in HCT116 cells involved activation of caspases, increased expression of BAX, mitochondrial cytochrome c and apoptosis inducing factor (AIF) release, while BCL-2 became down-regulated.	ziyuglycoside II	50-66	cytochrome c, somatic	Homo sapiens	169-181
31029785-6	2019	Apoptosis caused by p53 phosphorylation following ziyuglycoside II treatment in HCT116 cells involved activation of caspases, increased expression of BAX, mitochondrial cytochrome c and apoptosis inducing factor (AIF) release, while BCL-2 became down-regulated.	ziyuglycoside II	50-66	BCL2 apoptosis regulator	Homo sapiens	233-238
31029785-8	2019	Overall, these results suggest that ziyuglycoside II induces apoptosis through caspase-dependent and caspases-independent apoptosis, which was characterized by decreased expression of BCL-2, mitochondrial targeting, and altered production of ROS and translocation of AIF to the nuclei.	ziyuglycoside II	36-52	BCL2 apoptosis regulator	Homo sapiens	184-189
28718964-4	2017	The underlying antiangiogenic mechanism of ziyuglycoside II correlated with blocking vascular endothelial growth factor receptor-2 and the fibroblast growth factor receptor-1 mediated signaling pathway.	ziyuglycoside II	43-59	fibroblast growth factor receptor 1	Mus musculus	139-174
33941340-7	2021	EGFR signaling was suggested as the critical pathway underlying the anti-cancer effects of ZYG II and both docking simulation and western blot analysis demonstrated that ZYG II was a potential EGFR inhibitor.	ziyuglycoside II	91-97	epidermal growth factor receptor	Homo sapiens	0-4
24005866-5	2013	Subsequent apoptosis induced by ziyuglycoside II was accompanied with the activation of mitochondrial pathway, in particular a decreased mitochondrial membrane potential (MMP) as well as increased Bax/Bcl-2 ratio, cytochrome c release and the activity of caspase-3 and caspase-9.	ziyuglycoside II	32-48	BCL2 associated X, apoptosis regulator	Homo sapiens	197-200
24005866-5	2013	Subsequent apoptosis induced by ziyuglycoside II was accompanied with the activation of mitochondrial pathway, in particular a decreased mitochondrial membrane potential (MMP) as well as increased Bax/Bcl-2 ratio, cytochrome c release and the activity of caspase-3 and caspase-9.	ziyuglycoside II	32-48	BCL2 apoptosis regulator	Homo sapiens	201-206
24005866-5	2013	Subsequent apoptosis induced by ziyuglycoside II was accompanied with the activation of mitochondrial pathway, in particular a decreased mitochondrial membrane potential (MMP) as well as increased Bax/Bcl-2 ratio, cytochrome c release and the activity of caspase-3 and caspase-9.	ziyuglycoside II	32-48	cytochrome c, somatic	Homo sapiens	214-226
24005866-5	2013	Subsequent apoptosis induced by ziyuglycoside II was accompanied with the activation of mitochondrial pathway, in particular a decreased mitochondrial membrane potential (MMP) as well as increased Bax/Bcl-2 ratio, cytochrome c release and the activity of caspase-3 and caspase-9.	ziyuglycoside II	32-48	caspase 3	Homo sapiens	255-264
24005866-5	2013	Subsequent apoptosis induced by ziyuglycoside II was accompanied with the activation of mitochondrial pathway, in particular a decreased mitochondrial membrane potential (MMP) as well as increased Bax/Bcl-2 ratio, cytochrome c release and the activity of caspase-3 and caspase-9.	ziyuglycoside II	32-48	caspase 9	Homo sapiens	269-278
23969976-0	2013	Ziyuglycoside II-induced apoptosis in human gastric carcinoma BGC-823 cells by regulating Bax/Bcl-2 expression and activating caspase-3 pathway.	ziyuglycoside II	0-16	BCL2 associated X, apoptosis regulator	Homo sapiens	90-93
23969976-0	2013	Ziyuglycoside II-induced apoptosis in human gastric carcinoma BGC-823 cells by regulating Bax/Bcl-2 expression and activating caspase-3 pathway.	ziyuglycoside II	0-16	BCL2 apoptosis regulator	Homo sapiens	94-99
23969976-0	2013	Ziyuglycoside II-induced apoptosis in human gastric carcinoma BGC-823 cells by regulating Bax/Bcl-2 expression and activating caspase-3 pathway.	ziyuglycoside II	0-16	caspase 3	Homo sapiens	126-135
23969976-4	2013	Our results revealed that ziyuglycoside II could inhibit the proliferation of BGC-823 cells by inducing apoptosis but not cell cycle arrest, which was associated with regulation of Bax/Bcl-2 expression, and activation of the caspase-3 pathway.	ziyuglycoside II	26-42	BCL2 associated X, apoptosis regulator	Homo sapiens	181-184
23969976-4	2013	Our results revealed that ziyuglycoside II could inhibit the proliferation of BGC-823 cells by inducing apoptosis but not cell cycle arrest, which was associated with regulation of Bax/Bcl-2 expression, and activation of the caspase-3 pathway.	ziyuglycoside II	26-42	BCL2 apoptosis regulator	Homo sapiens	185-190
23969976-4	2013	Our results revealed that ziyuglycoside II could inhibit the proliferation of BGC-823 cells by inducing apoptosis but not cell cycle arrest, which was associated with regulation of Bax/Bcl-2 expression, and activation of the caspase-3 pathway.	ziyuglycoside II	26-42	caspase 3	Homo sapiens	225-234
24680927-0	2014	Ziyuglycoside II induces cell cycle arrest and apoptosis through activation of ROS/JNK pathway in human breast cancer cells.	ziyuglycoside II	0-16	mitogen-activated protein kinase 8	Homo sapiens	83-86
24680927-5	2014	Ziyuglycoside II treatment also induced reactive oxygen species (ROS) production and apoptosis by activating the extrinsic/Fas/FasL pathway as well as the intrinsic/mitochondrial pathway.	ziyuglycoside II	0-16	Fas ligand	Homo sapiens	127-131
24680927-6	2014	More importantly, the c-Jun NH2-terminal kinase (JNK), a downstream target of ROS, was found to be a critical mediator of ziyuglycoside II-induced cell apoptosis.	ziyuglycoside II	122-138	mitogen-activated protein kinase 8	Homo sapiens	22-47
24680927-6	2014	More importantly, the c-Jun NH2-terminal kinase (JNK), a downstream target of ROS, was found to be a critical mediator of ziyuglycoside II-induced cell apoptosis.	ziyuglycoside II	122-138	mitogen-activated protein kinase 8	Homo sapiens	49-52
24680927-8	2014	Taken together, the cell death of breast cancer cells in response to ziyuglycoside II was dependent upon cell cycle arrest and cell apoptosis via a ROS-dependent JNK activation pathway.	ziyuglycoside II	69-85	mitogen-activated protein kinase 8	Homo sapiens	162-165
33941340-7	2021	EGFR signaling was suggested as the critical pathway underlying the anti-cancer effects of ZYG II and both docking simulation and western blot analysis demonstrated that ZYG II was a potential EGFR inhibitor.	ziyuglycoside II	170-176	epidermal growth factor receptor	Homo sapiens	0-4
33941340-7	2021	EGFR signaling was suggested as the critical pathway underlying the anti-cancer effects of ZYG II and both docking simulation and western blot analysis demonstrated that ZYG II was a potential EGFR inhibitor.	ziyuglycoside II	170-176	epidermal growth factor receptor	Homo sapiens	193-197